Composition, form of production and packaging
Solution for infusions is transparent, colorless, odorless.
sodium fumarate 14 g
Sodium Chloride 6 g
potassium chloride 300 mg
magnesium chloride 120 mg
400 ml - bottles for blood substitutes.
450 ml - bottles for blood substitutes.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2005.
The drug for correction of water-salt metabolism, which helps to reduce tissue hypoxia.
Sodium fumarate is found in all cells of the body with aerobic respiration, contributes to the elimination of acidemia by chemical neutralization of acid metabolites like sodium lactate and sodium acetate (components widely used in the manufacture of saline solutions).
The drug reduces the viscosity of the blood and improves its rheological properties, as well as improves the parameters of hemodynamics, has a diuretic and detoxification effect.
Data on the pharmacokinetics of the drug Mafusol are not available.
Hypovolemic and hypoxic states of different etiology:
- Loss of water;
-Shock (hemorrhagic, burn, traumatic, operating);
-intoxication (including with peritonitis, sepsis, intestinal obstruction);
As a component of the perfusion mixture for filling the device of artificial circulation.
The drug is administered intravenously and intravenously. Doses and the speed of administration are set individually, depending on the indications and the patient's condition.
In the shock of mild to moderate severity, the drug is injected into / a and / in the struino. After the normalization of the parameters of hemodynamics - in / in the drip in a daily dose of up to 2-2.5 liters. In severe shock, the administration of Mafusol (at least 1 L / day) is combined with the administration of blood and colloid blood substitutes for hemodynamic action.
In severe intoxication, the drug is administered at a dose of up to 2-3 l / day in combination with other detoxification preparations.
When filling the apparatus of artificial circulation, Mafusol makes up to 50-70% of the total volume of the perfusion solution introduced into the apparatus.
When applied according to the indications in the recommended doses, no side effect was noted.
Conditions in which a large amount of liquid should not be introduced into the body, including:
-increase of intracranial pressure with closed trauma of the skull;
-chronic heart failure in decompensation.
PREGNANCY AND LACTATION
Safety and effectiveness of the drug during pregnancy and lactation are not established.
Mafusol can be used in combination with blood and colloid blood substitutes for hemodynamic action, as well as in combination with other detoxification agents.
Data on the overdose of the drug Mafusol is currently absent.
Drug interaction of the drug has not been studied.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored in a dry place inaccessible to children at a temperature of 0 В° to 25 В° C. Freezing is allowed. Shelf life - 2 years.
Conditions of leave from pharmacies
The drug is released by prescription.